Kairos Pharma to Attend Global Conference, Showcases Breakthrough Cancer Treatment
Kairos Pharma to present groundbreaking cancer treatment at D. Boral Capital Inaugural Global Conference, showcasing ENV105 targeting CD105 to overcome drug resistance in cancer treatments. Learn more about the innovative approach and potential impact on prostate and lung cancer therapy.
This news matters as it highlights Kairos Pharma's innovative approach to combating drug resistance in cancer treatment. Investors can gain insights into the company's promising lead candidate, ENV105, which aims to address significant unmet medical needs in prostate and lung cancer therapy.
